R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Respiratory - Small molecules (13)

Modality Indication Targets Stage Company Project No. Detail
1 Phase 2a (therapeutic exploratory) trial of SB17170 in patients with idiopathic pulmonary fibrosis
Small molecules IPF HMGB1 Phase 2 RS-2026-25502804
2 Development of a Pre-clinical Candidate for Progressive Fibrosing Interstitial Lung Disease Targeting gp130 (an IL-6 Family Cytokine) Inhibition
Small molecules Auto-immune Diseases & Progressive Fibrosing Interstitial Lung Disease gp130 Candidate Primo Thera CO., Ltd. RS-2025-25452684
3 Development of Selective PDE-4B Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Small molecules Idiopathic pulmonary fibrosis PDE-4B Candidate Jeil Pharmaceutical RS-2025-02213196
4 Discovery of a novel small-molecule drug candidate targeting IL-33
Small molecules Asthma IL-33 Candidate Azcuris Co., Ltd. RS-2024-00333140
5 Discovery of a ‘First.In.Class’ New Drug for IPF Treatment
Small molecules Idiopathic pulmonary fibrosis ARPC2 Candidate SapiensBio.Inc RS-2023-00283815
6 Phase I clinical study of SB17170 for the drug development for idiopathic pulmonary fibrosis
Small molecules Idiopathic pulmonary fibrosis HMGB1 Phase 1 SPARK Biopharma RS-2023-00259223
7 Development of Novel Agents for Idiopathic Pulmonary Fibrosis: Phase 2a Clinical Trial and phase 2b approval of BBT-877, autotaxin inhibitor, in IPF patients
Small molecules Idiopathic pulmonary fibrosis Autotacxin Phase 2 Bridge Biotherapeutics, Inc. RS-2023-00219938
8 Clinical Trial Development of A Novel Small Molecule Inhibitor for Idiopathic Pulmonary Fibrosis Treatment
Small molecules IPF Prolyl-tRNA synthetase (PRS) Phase 2 Daewoong Pharmaceutical Co., Ltd. RS-2022-00166689
9 ATB-610: Small molecule developing as a inhaler with reducing toxicity by inhibiting ALK5 selectively for IPF treatment
Small molecules IPF ALK5 Candidate Autotelic Bio RS-2022-00165740
10 Development of drug candidate against respiratory infection using Foxj1 as a target
Small molecules Pneumonia Foxj1 Lead Chonnam National University HN21C0513
11 Elicitation of lead compounds for the treatment of chronic obstructive pulmonary disease targeting leucotriene B4 receptor BLT2
Small molecules COPD BLT2 Lead Korea university HN21C0996
12 Study on lead generation for IPF (idiopathic pulmonary fibrosis) drug based on AI platform
Small molecules IPF CHIT1 Lead INNOVO Therapeutics HN21C0205
13 Development of small-molecule asthma drug that inhibits the binding of IL-33 to its receptor
Small molecules Asthma IL-33 Lead AZCURIS HN21C0187
BACK